What type of study is this?

December 8, 2025Blood

Efficacy of crizanlizumab in preventing vaso-oclusive crisis and hospitlalizations in sickle cell disease

View Full Paper

Ask AI

Bookmark

Authors

RJReyad Al JabiriLincoln Medical Center FAFAIQ ALDARAB'AHLincoln Medical Center

Discussion

Member takes

Implication

Retrospective cohort analysis reveals increased vaso-occlusive crises and hospitalizations in patients on crizanlizumab, indicating need for alternate therapeutics.

Key Points

Patients receiving crizanlizumab had higher rates of vaso-occlusive crisis and hospitalizations over multiple time points, contrasting with those not treated.
The analysis involved 2,036 sickle cell anemia patients, revealing significant discrepancies in clinical outcomes between treatment cohorts.
Using propensity score matching, results highlighted elevated relative risks for crises and hospitalizations in crizanlizumab recipients at 3, 6, 12, and 36 months.
The findings prompt a reconsideration of crizanlizumab's efficacy and underline the necessity for innovative treatment options for sickle cell disease.

Cite This Study

Jabiri et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2f8 https://doi.org/10.1182/blood-2025-7962

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort analysis reveals increased vaso-occlusive crises and hospitalizations in patients on crizanlizumab, indicating need for alternate therapeutics.

Efficacy of crizanlizumab in preventing vaso-oclusive crisis and hospitlalizations in sickle cell disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of crizanlizumab in preventing vaso-oclusive crisis and hospitlalizations in sickle cell disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider